Lee et al. reported results from a Phase I study in patients with AML, myelodysplastic syndromes (MDS), and chronic myelogenous leukemia (CML), in which alloreactive haploidentical NK cells (CD3 depleted and CD56 selected) were administered along with IL-2 injections, followed by thymoglobulin conditioning and allogeneic HSCT. The gene discussed is IL2; the disease is acute myeloid leukemia.